Telix Pharmaceuticals Securities Class Action
Analysis based on 7 articles · First reported Nov 20, 2025 · Last updated Jan 02, 2026
The market is negatively impacted by the alleged misstatements and regulatory actions against Telix Pharmaceuticals, leading to significant drops in its stock price. This event highlights the risks associated with pharmaceutical development and supply chain integrity, potentially increasing investor scrutiny on similar companies.
Telix Pharmaceuticals is facing a federal securities class action lawsuit initiated by Faruqi & Faruqi. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding the progress of its prostate cancer therapeutic candidates and the quality of its supply chain and partners. This follows a subpoena from the United States — United States Securities and Exchange Commission on July 22, 2025, concerning disclosures about its prostate cancer therapeutics, which caused a 13% drop in Telix Pharmaceuticals's American Depositary Shares. Further, on August 28, 2025, the United States — Food and Drug Administration issued a Complete Response Letter for Telix Pharmaceuticals's product TLX250-CDx, citing deficiencies in its Chemistry, Manufacturing, and Controls package and issues with two third-party manufacturing partners, leading to an additional 21% decline in Telix Pharmaceuticals's ADSs. Investors who suffered losses between February 21, 2025, and August 28, 2025, are encouraged to seek lead plaintiff status by January 9, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard